SiDMAP Collaboration with National Cancer Institute to Be Presented at the 2013 World Biotechnology Conference

LOS ANGELES--(BUSINESS WIRE)--SiDMAP, LLC, a leading provider of metabolic profiling and biomarker development services to the pharmaceutical, academic, governmental, and biotechnology industries, announced today that it will present results of a single ¹³C glucose tracer study performed in collaboration with scientists at the National Cancer Institute.

SiDMAP will deliver a section lecture at the World Biotechnology Conference in the Medical Biotechnology venue. The Conference will take place on June 3-6, 2013, at the John B. Hynes Memorial Convention Center, in Boston, MA. The talk is titled “Stable ¹³C Isotope Enriched Metabolome (Isotopolome) Wide Associations (IWAS) Improve System Wide Association Studies (SWAS) for Phenotype and Drug Research,” and it introduces an integrated metabolic marker discovery tool, EZTopolome^TM.

The tool uses ¹³C labeled metabolome (isotopolome) wide associations for visualizing unique metabolic phenotypes. In this study, EZTopolome^TM provided unique insights into a kidney cancer phenotype. Kidney tumor cells harbor mutations that render a key TCA cycle enzyme defective, after which tumor cells revert to alternate molecule synthesis pathways for proliferation. The phenotype has previously been characterized and published using multiple metabolic tracer experiments (Nature. 481:385-388, 2011. doi: 10.1038/nature10642).

“In the future, it may be possible to screen tumor cell metabolic profiles and determine their response to treatments, by visualizing very specific metabolic adaptive changes to oncogenic associations using a single ¹³C tracer method and presented using EZTopolome^TM,” said Laszlo G. Boros, M.D., SiDMAP’s Chief Scientific Advisor.

About SiDMAP

SiDMAP provides flux-based, metabolic profiling services to pharmaceutical, biotech and research organizations seeking to enhance their drug development processes, and develop further insights into a drug’s mechanism of action and disease states. SiDMAP’s unique tracer technology measures metabolic pathway flux to gain unique insights into cell function. A SiDMAP assay provides clients with an accurate, dynamic metabolic analysis of a compound’s biological impact in both in vitro and in vivo systems, before a company spends millions more on development and clinical trials. SiDMAP is headquartered in Los Angeles, California.